PharmaVOICE - 
September 2009
Purchase Issue

In Every Issue
Last Word
Making the Connection How does the diversity program alliance between [...]
By
Talent Pool
talent pool executive appointments and promotions in the healthcare industry [...]
By
PharmaTrax
Biopharma Firms Increasingly Seek Marketing Role in Licensing Deals Large [...]
By
E-Media
New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: [...]
By
What’s New
New healthcare-related products, services, and companies FDA Anticounterfeiting Draft Focuses [...]
By
UpFront
FDA Vision 6-part Plan to Support Public Health Commissioner of [...]
By
Letter from the Editor
A Cautionary Tale Commissioner of Food and Drugs Margaret A. [...]
By

Taren Grom, Editor

On The Cover

REMS Take Hold
The new legislation surrounding tougher REMS requirements is expected to effect marketing as well as drug development— but the impact might not be all bad. Risk Evaluation and Mitigation Strategies REMS Take Hold BY ROBIN ROBINSON “The key to mitigating risk is applying a rigorous, science-based approach to understanding how physicians and patients actually use [...]
By

Robin Robinson

Features

Letter from the Editor
A target-rich environment
By
DIA Recap
The 2009 DIA Annual Conference San Diego Played Host to the 45th Anual Drug Information Association Meeting Thought Leaders Raise Their VOICE at DIA EDITOR’S TAKE VIDEO CLIPS pharmavoice.com Aureus Research Consultants Alicia Pouncey Alicia discusses using medical simulation for CRA training. Bioclinica Mark Weinstein Mark talks about the intersection of medical imaging and electronic [...]
By
The Knowledge Revolution
In 20 to 25 years, pharmaceutical research and development will be multidimensional. Scientists will use artificial intelligence and robotics and interact through a global networked Web. Modeling and simulations that work at different levels, including digital models of “virtual patients,” will be common. These simulations will speed experimentation and help predict safety and efficacy of [...]
By

Denise Myshko

Recognizing the Value of CME
SPONSOR: Medscape LLC, an accredited provider of continuing medical education. In 2008, Medscape LLC issued 5.2 million CME/CE certificates. www.medscapecme.comReferences: Accreditation Council for Continuing Medical Education. ACCME Annual Report Data 2004-2008. Available at http://www.accme.org/dir_docs/doc_upload/207fa8e2-bdbe-47f8-9b65-52477f9faade_uploaddocument.pdf. Accessed August 4, 2009. SPONSOR: Medscape LLC, an accredited provider of continuing medical education. In 2008, Medscape LLC issued 5.2 million [...]
By

Ezra T. Ernst

Adult Distance Learning in Promotional Education Programs
ProCom, part of CommonHealth Adult Distance Learning in Promotional Education Programs Karen Sullivan Editor/Writer, ProCom, part of CommonHealth Michael Zilligen General Manager, ProCom, part of CommonHealth Healthcare practitioners (HCPs) are constantly looking for the most current medical information, but are short on time to acquire it. With the advent of the Internet, medical education developers [...]
By

Karen Sullivan and Michael Zilligen

Increased Regulation and Mature Web Technology: Fertile Ground for a New Generation of Clinical Opinion Leader Engagements
Mary Manna Anderson President, HLS, part of CommonHealth A heightened interest and concern about conflicts of interest between physicians and industry has led to increased federal, state and institution guidelines designed to monitor, and in some cases, limit, clinicians’ interactions with industry. These guidelines are a catalyst for industry to reassess approaches to engaging thought [...]
By

Mary Manna Anderson

View on Med Ed: The Devil is in the Details
The Devil is in the Details The ongoing effort by accreditation and monitoring groups to separate commercial interests from continuing medical education (CME) funding appears to be raising as many questions as answers. by Carolyn Gretton It has been a year since Pfizer rocked the CME sector by announcing it would no longer fund physician [...]
By

Carolyn Gretton

Jeff George: Stamping a Brand on Generics
Stamping a BRAND on GENERICS BY KIM RIBBINK Leading a generics company today is a very different undertaking compared with a few years ago. Once considered interlopers in the pharmaceutical industry, generics companies are now big business and are playing a leading role in healthcare decision making. And Sandoz, a Novartis company, is one of [...]
By

Kim Ribbink

Patient Recruitment: Strategies for Multinational Studies
Finding appropriate study subjects is still one of the biggest stumbling blocks for timely and efficient drug development. Recruiting patients for multinational trials can be even more daunting, since global trials add to the complexity. While experts say some issues are no longer an obstacle — such as technology infrastructure or finding trained investigators in [...]
By

Denise Myshko

What is the Business Case for Tweeting?
As of August 2009, only 18 pharmaceutical companies were using Twitter, only a few of those were actively Tweeting, and only one encompassed a branded effort. Johnson & Johnson has been the most active, with daily Tweets from Director, Media Relations Marc Monseau and Director, Video Communications Rob Halper. Novo Nordisk was the first pharma [...]
By

Robin Robinson

FEEDBACK